Guardant Health, Inc. articles

As Colorectal Cancer Awareness Month closes, Guardant Health reflects on the journey to develop a blood-based test for colorectal cancer screening. Over the last decade, the effort culminated in an approach that is now FDA-approved, guideline-recommended, and reimbursable, enabling the launch of Shield to support earlier detection and improved outcomes.

Early Detection Improves Outcomes, Yet a Large Segment Remains Unscreened

Early detection in colorectal cancer yields a